Challenges in developing Geroscience trials

Review article https://doi.org/10.1038/s41467-023-39786-7 Challenges in developing Geroscience trials Received: 20 February 2023 Yves Rolland 1,2 , Felipe Sierra3, Luigi Ferrucci 4, Nir Barzilai5, Rafael De Cabo6, Joan Mannick7, Anthony Oliva8, William... More

Review article https://doi.org/10.1038/s41467-023-39786-7 Challenges in developing Geroscience trials Received: 20 February 2023 Yves Rolland 1,2 , Felipe Sierra3, Luigi Ferrucci 4, Nir Barzilai5, Rafael De Cabo6, Joan Mannick7, Anthony Oliva8, William Evans9, Davide Angioni1, Accepted: 29 June 2023 Philipe De Souto Barreto1,2, Jeremy Raffin1,2, Bruno Vellas1,2, James L. Kirkland 10 & the G.C.T-TF group* Check for updates Geroscience is becoming a major hope for preventing age-related diseases and loss of function by targeting biological mechanisms of aging. This unprece- dented paradigm shift requires optimizing the design of future clinical studies related to aging in humans. Researchers will face a number of challenges, 1234567890():,; 1234567890():,; including ideal populations to study, which lifestyle and Gerotherapeutic interventions to test initially, selecting key primary and secondary outcomes of such clinical trials, and which age-related biomarkers are most valuable for both Less